Press release article from our research archive:

Cerus Commences Clinical Trials for Red Blood Cell Pathogen Inactivation Program.

Company to Present Preclinical Data at the American Society

Of Hematology Meeting

MIAMI, Dec. 7 /PRNewswire/ -- Cerus Corporation (Nasdaq: CERS) announced today that it has commenced a Phase 1a clinical trial of its red blood cell pathogen inactivation system. The trial is a randomized, controlled study designed to evaluate the post-transfusion viability of red blood cells treated with the company's system and includes approximately 40 healthy subjects. The study subjects are receiving a transfusion of either standard red blood cells or red blood cells treated with the company's pathogen inactivation system. The level of circulating transfused red blood cells is ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!